© 2020 MJH Life Sciences and . All rights reserved.
Quiz: Evolving Treatment Options in BRAF V600E Mutant Metastatic Colorectal Cancer
Quiz: Evolving Treatment Options in BRAF V600E Mutant Metastatic Colorectal Cancer
April 17, 2020
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the BRAF V600E mutation in patients with colorectal cancer.
In our gastrointestinal cancer quiz, you’ll get a chance to test your knowledge on the BRAF V600E mutation in patients with colorectal cancer. Here’s your first question:
1. What combination treatment was studied in the BEACON CRC study of patients with BRAF V600E mutated metastatic colorectal cancer?
A. Encorafenib (Braftovi), cetuximab (Erbitux), and binimetinib (Mektovi)
B. Vemurafenib (Zelboraf), dabrafenib, and trametinib
C. Dabrafenib, cetuximab, and encorafenib
D. Vemurafenib, trametinib, and binimetinib